Editas Medicine Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.7%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.00next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| EDIT-401 First-in-Human Clinical Trial Initiation | 31 Dec 2026 |
| EDIT-401 Early Human Proof-of-Concept Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
EDIT-401 Preclinical LDL-C Reduction Annually90.0Target: Maintain high efficacy in human trials
Cash and Cash Equivalents (USD Millions) Quarterly123.6Target: Sufficient to fund operations into Q3 2027
Quarterly Net Loss (USD Millions) Quarterly25.0Target: Narrowing loss through disciplined cost management
Watch Items
- EDIT-401 Australian Clinical Trial Notification (CTN) SubmissionTrigger: Submission finalized and accepted by the TGAAction: Verify regulatory clearance to initiate the first-in-human Phase 1/2 clinical trial in Australia.
- EDIT-401 Early In Vivo Human Proof-of-Concept DataTrigger: Initial clinical data release showing LDL-C reduction in patientsAction: Evaluate clinical efficacy and safety profile to validate the company's in vivo upregulation strategy.
- Warrant Expiration Trigger for May 2026 Public OfferingTrigger: Phase 1 clinical data showing >=3 patients with >80% LDL-C reduction and >=1 month follow-upAction: Monitor for warrant expiration 30 days post-announcement, which could bring in up to $194.4 million in additional gross proceeds.
Research as of 20 Jun 2026